about
First-in-Class Inhibitors of Sulfur Metabolism with Bactericidal Activity against Non-Replicating M. tuberculosisAntiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug RepositioningComputational Discovery of Putative Leads for Drug Repositioning through Drug-Target Interaction PredictionRepositioning: the fast track to new anti-malarial medicines?Exploring anti-malarial potential of FDA approved drugs: an in silico approach.Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells.Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay.Drug repositioning as a route to anti-malarial drug discovery: preliminary investigation of the in vitro anti-malarial efficacy of emetine dihydrochloride hydrate.In vitro susceptibility of Mycobacterium tuberculosis to trimethoprim and sulfonamides in FranceArtemisinin derivatives: a patent review (2006 - present).Recent advances in the research of heterocyclic compounds as antitubercular agents.Biotransformation and biocatalysis: roles and applications in the discovery of antimalarials.Metabolomic-based strategies for anti-parasite drug discovery.Chloroquine-containing compounds: a patent review (2010 - 2014).Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need.Amodiaquine-Ciprofloxacin: a potential combination therapy against drug resistant malaria.Drug repurposing in idiopathic pulmonary fibrosis filtered by a bioinformatics-derived composite score.Design, synthesis, and in vitro antituberculosis activity of benzo[6,7]cyclohepta[1,2-b]pyridine-1,3,4-oxadiazole derivatives.Interview with Future Medicinal Chemistry's US Senior Editor, Iwao Ojima. Interview by Issac Bruce.Drugs for neglected diseases: part II.Design, Synthesis, and Biological Evaluation of 1,4-dihydropyridine Derivatives as Potent Antitubercular Agents.Repurposing Strategy of Atorvastatin against Trypanosoma cruzi: Monotherapy and Combined Therapy with Benznidazole Exhibit Synergistic Trypanocidal ActivityCurrent and Future Strategies for Improving Drug Discovery Efficiency
P2860
Q28354028-4CAF2D67-4BAF-4B8D-B803-86177C7A4A38Q28547217-87450C72-029F-4FE0-B509-09292973D8C3Q28554438-1B88B34C-252A-4B0F-B0ED-ACFF3C99EBAAQ33612012-0588C6D0-DBD3-4436-98B5-C4E201259A34Q33916846-6BA5AC90-887C-4FBD-916F-DCF49D2549EBQ34501206-CF2203A0-BB58-4388-A7C8-C4CFBB2FD772Q34781823-CC18CFED-1B1A-4B8B-BEC9-A8F0F7024C44Q35012561-006B4979-45D8-4475-8375-9924127CCDBDQ37335885-3E86623C-BC9A-4677-B169-BA04CDEAE9DEQ38042732-5CC5B75E-3A12-4CF8-A4A4-27B399E04BE4Q38050102-A0FD2EC6-1554-46B0-9B91-C1386B9E6335Q38066995-6A09131F-91B6-4AC3-9730-6394AFD07A4DQ38256642-A3300D38-4B40-4C79-A65B-46971D7BB181Q38503439-946390E0-5B91-4C69-882D-1CD9C90B53C9Q39003990-907CF45E-439B-44AB-9EA6-6BBEEE41488DQ41452469-FB7E9373-8F9D-4656-AF07-3A8CB4D7E8F2Q42282467-402C8C3E-ACC2-4A2C-9CC5-A5155C68ABC5Q48154153-80059359-3D5D-4DD4-9919-18D629E843DEQ48409114-B65732EF-2F79-45C6-930C-04339B3F20DFQ51682619-F301E4E8-FAA4-4EFB-B8BC-E397626FBE80Q52980622-E96D82A1-78CD-483F-83AF-8D9E25546C83Q57167324-C016CE60-D17D-4648-B9A9-D342FE00C793Q58636775-07A9A750-4D98-4071-B58B-7532DC50B4F7
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Drug repositioning in the treatment of malaria and TB.
@en
Drug repositioning in the treatment of malaria and TB.
@nl
type
label
Drug repositioning in the treatment of malaria and TB.
@en
Drug repositioning in the treatment of malaria and TB.
@nl
prefLabel
Drug repositioning in the treatment of malaria and TB.
@en
Drug repositioning in the treatment of malaria and TB.
@nl
P2860
P356
P1476
Drug repositioning in the treatment of malaria and TB.
@en
P2093
Alexis Nzila
Zhenkun Ma
P2860
P304
P356
10.4155/FMC.11.95
P577
2011-09-01T00:00:00Z